More about Abbott India Limited
Fundamentals for Abbott India Limited
Regulatory Filings for Abbott India Limited
From Cost Center to Strategic Core: The Top 10 Trends Transforming Finance in 2026
CFOs Seize the Tech Purse Strings: How 2026 Budgets Are Fueling the AI Transformation
From Agentic AI to Tokenized Assets: The Fintech Trends Reshaping Financial Services
Forex Focus: How a Weakening Indian Rupee Could Reshape Markets in Q1 2026
Fundamentals for Abbott India Limited
Business Operations:
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It provides anti-infective, cardio-diabeto, hepatology, hormones, neuro-psychiat, hepatic, gennext, and consumer care products. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited is a subsidiary of Abbott Capital India Limited.
Revenue projections:
Abbott India Limited's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.
Financial Ratios:
| currentRatio | 0.00000 |
|---|---|
| forwardPE | 32.18395 |
| debtToEquity | 4.54900 |
| earningsGrowth | 0.04200 |
| revenueGrowth | 0.06800 |
| grossMargins | 0.46409 |
| operatingMargins | 0.25794 |
| trailingEps | 717.85000 |
| forwardEps | 817.02220 |
With positive gross and operating margins, Abbott India Limited demonstrates strong profitability. This reflects the company's ability to manage costs and maintain healthy profits, showcasing effective operational efficiency and financial stability.
Abbott India Limited's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that Abbott India Limited's financial performance will improve in the current financial year.
Price projections:
ABBOTINDIA's price has consistently hovered around the lower limit of price projections. This pattern suggests that the stock may be underperforming relative to expectations, which could lead to concerns among investors.
Recommendation changes over time:
Analysts are favoring ABBOTINDIA with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider ABBOTINDIA as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
Understanding Divergent House Price Movements Worldwide
The 2026 Tariff Tipping Point: When Trade Policy Reaches the Consumer
From Caracas to Commodities: The Market Impact of U.S.–China Friction